Akeso (FRA:4RY) Quality Rank


FRA:4RY Akeso Inc FRA:4RY
51 GF Score
Price €10.77
GF Value €16.19
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Akeso Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Akeso Quality Rank Related Terms

FRA:4RY
51GF Score
Akeso Inc FRA:4RY
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €10.77 is trading 33.5% below its estimated GF Value™ of €16.19. GuruFocus considers Akeso to be Possible Value Trap.

Key valuation signals for FRA:4RY:

  • Quality Rank:
  • GF Value™: €16.19 vs. price of €10.77 (33.5% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
51GF Score

Get the complete analysis for FRA:4RY

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.77
Price
€16.19
GF Value